drugset
Drugs / Human BCMA targeted T Cells Injection
last change Jul 2024 re-read 3 minutes ago

Human BCMA targeted T Cells Injection

Cell therapy

Developed for
plasma cell myeloma
Investigated by
First Affiliated Hospital of Wenzhou Medical University · Hrain Biotechnology Co., Ltd. · Shanghai Changzheng Hospital · The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine

Trials 1

today NCT04003168 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04003168 Jul 2019 → Jul 2022 plasma cell myeloma Hrain Biotechnology Co., Ltd. Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Human BCMA targeted T Cells Injection ClinicalTrials.gov intervention name — accepted as the source's own label NCT04003168 ↗
Action Deplete “CAR-T cells are genetically modified T cells with redirected specificity and potent T-cell-mediated cytotoxicity toward malignant cells.” PMID 36536403 ↗ Dec 2022
Modality Cell therapy “CAR-T cells are genetically modified T cells with redirected specificity and potent T-cell-mediated cytotoxicity toward malignant cells.” PMID 36536403 ↗ Dec 2022
Route Intravenous “administered intravenously” NCT04003168 ↗